If the stock market is any guide, Sharvil Patel has just inherited one of the top generic drug manufacturers in the world. And besides, with three generations in the generic drug business, they’ve seen hard times before. "You see it with his relationship with his father, my grandfather, you see it when you come to work. That’s part of about 40 generic drug applications the company has before the FDA, any of which they say could be approved this year. "Founded when Pankaj Patel’s father, Ramanbhai, left his academic job at a local school of pharmacy in 1952, the firm now has a market value of almost $8 billion and annual revenue of about $1.4 billion.

Source: Economic Times August 10, 2017 05:32 UTC